Evotec SE has nominated a small-molecule preclinical development candidate from its drug-discovery alliance with Spain’s Almirall SA aimed at immune-mediated inflammatory skin diseases. The companies are working on multi-target treatments in medical dermatology, an area where newer oral therapies are being pursued alongside established biologic drugs for conditions such as atopic dermatitis and other inflammatory disorders. Evotec said the joint team moved from early leads to the candidate...